{"groups":[{"description":"Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone \\[LHRH\\] agonist therapy, LHRH antagonist therapy, or surgical castration). Patients also receive docetaxel IV over 1 hour on day 1. Treatment with docetaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Androgen-Deprivation Therapy and Docetaxel"},{"description":"Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone \\[LHRH\\] agonist therapy, LHRH antagonist therapy, or surgical castration).","id":"FG001","title":"Androgen-Deprivation Therapy Alone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"0"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"0"}],"type":"Never started treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Complicating disease"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Non-compliance"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Chemotherapy discontinued only"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"397"},{"groupId":"FG001","numSubjects":"393"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"390"},{"groupId":"FG001","numSubjects":"392"}],"type":"Toxicity Analysis"},{"achievements":[{"groupId":"FG000","numSubjects":"334"},{"groupId":"FG001","numSubjects":"299"}],"type":"Both Baseline and 3-month FACT-P Evals"},{"achievements":[{"groupId":"FG000","numSubjects":"335"},{"comment":"Arm B tx info was not collected so only 1 patient w/o follow-up data was considered \"not completed\".","groupId":"FG001","numSubjects":"392"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"62"},{"groupId":"FG001","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"This study was activated on July 28, 2006, accrued its first patient on September 26, 2006, and closed to accrual on November 21, 2012, after accrual of 790 patients."}